Enrollment Completed Utilizing Cytori’s Adipose-Derived Stem Cell Technology for Treatment of Breast Cancer Complications
News Nov 15, 2006
Cytori Therapeutics, Inc. was informed of the completion of enrollment of the 11 patient investigator-initiated RESTORE study in Japan using adipose-derived stem cells to treat the complications of surgery and radiation damage following partial mastectomy for the treatment of breast cancer.
The administered cells were extracted and concentrated from the patients’ own adipose tissue using Cytori’s stem cell processing system.
“In the first 11 patients, clinical follow up indicates that the therapy is safe and well tolerated,” said Keizo Sugimachi, M.D., lead investigator and President, Kyushu Central Hospital.
“It appears that adipose-derived stem cells can treat the side effects of surgery and radiation therapy, which includes breast disfigurement, tissue loss, pain and other complications of cancer treatment. The stem cells, which were extracted and processed, using Cytori’s technology, appear to improve the outcome of these patients.”
“We are highly encouraged by this report,” said Marc Hedrick, M.D., President of Cytori Therapeutics. “Based on this information, Cytori intends to sponsor a formal clinical study to further assess the potential for adipose-derived stem cells in this field and to support market adoption and reimbursement for this significant unmet medical need.”
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.